Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
David G. Maloney(Fred Hutch Cancer Center), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Firoozeh Sahebi(City Of Hope National Medical Center), Benedetto Bruno(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Stephen J. Forman(City Of Hope National Medical Center), Thomas R. Chauncey(City Of Hope National Medical Center), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Barry E. Storer(City Of Hope National Medical Center), Ute Hegenbart(Heidelberg University), Brenda M. Sandmaier(University of Washington), Keith Stockerl‐Goldstein(City Of Hope National Medical Center), Arthur J. Molina(City Of Hope National Medical Center), Peter A. McSweeney(Colorado Blood Cancer Institute), Karl G. Blume(City Of Hope National Medical Center), William Bensinger(Swedish Medical Center), George Somlo(City Of Hope National Medical Center)
Cited by 407
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k